Currently approved PARP inhibitors for ovarian cancer, such as olaparib, niraparib, and rucaparib, have demonstrated significant clinical efficacy, particularly in patients with BRCA1/2 mutations, where they effectively induce tumor cell death through the synthetic lethality mechanism (52, 53). This evidence concerns the gene BRCA1 and neoplasm.